Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Lazertinib and Pemetrexed/Carboplatin Combination in Patients With EGFR Positive, Metastatic NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of Osimertinib

NCT05477615 is registered in ClinicalTrials.gov with Jin Hyoung Kang as lead sponsor.

NCT NCT05477615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05477615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Lazertinib and Pemetrexed/Carboplatin Combination in Patients With EGFR Positive, Metastatic NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of Osimertinib
Lead sponsor
Jin Hyoung Kang
Phase
Phase 2
Overall status
Terminated
Start date
August 12, 2022
Completion date
October 10, 2025
Enrollment
14 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer